Stone-Elander S, Thorell J O, Eriksson L, Fredholm B B, Ingvar M
Karolinska Pharmacy, Stockholm, Sweden.
Nucl Med Biol. 1997 Feb;24(2):187-91. doi: 10.1016/s0969-8051(96)00216-8.
(KF 17837, (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine, was 11C-labelled by methylation at N-7 of the nor-compound, KF 17440, using [11C]methyl iodide. Radiochemical conversions of 50% or 70-80% were obtained using sodium hydride or potassium carbonate, respectively, as base. Total synthesis time was 40-45 min, including isolation by semipreparative liquid chromatography. Cerebral uptake of [N-11C-methyl]KF 17837 in Cynomolgus monkeys, evaluated using positron emission tomography (PET), was so low that regional differences in distribution kinetics were revealed first after increasing injected dose 3-fold and using 3-D mode of data acquisition. At all times, the relative regional retention (maximum striatum:cerebellum: cortex approximately 1.1:1:0.8 at 20 min) was considerably different from the known relative density of A2A receptors in these regions. Radioactivity decreased more rapidly in the cortex than in the striatum and cerebellum (by 20% vs. 3-7%, respectively, between 5 and 50 min). Addition of carrier to [N-11C-methyl]KF 17837 only marginally affected the cerebral radiotracer uptake. By contrast, in the heart the initial tracer uptake was high and the elimination kinetics was enhanced by adding unlabelled carrier. We have thus shown that KF 17837 passes the blood-brain barrier, though to a very low extent. This fact and the apparently high nonspecific binding in vivo of [N-11C-methyl]KF 17837 in regions with low receptor densities limits its usefulness as a ligand for quantification of the adenosine A2A receptors in the primate brain.
KF 17837,即(E)-8-(3,4-二甲氧基苯乙烯基)-1,3-二丙基-7-甲基黄嘌呤,是通过使用[11C]甲基碘对去甲化合物KF 17440的N-7位进行甲基化反应来进行11C标记的。分别使用氢化钠或碳酸钾作为碱时,放射性化学转化率分别为50%或70 - 80%。总合成时间为40 - 45分钟,包括通过半制备液相色谱进行分离。使用正电子发射断层扫描(PET)评估食蟹猴脑中[N-11C-甲基]KF 17837的摄取量非常低,以至于在将注射剂量增加3倍并使用三维数据采集模式后,才首次揭示了分布动力学的区域差异。在所有时间点,相对区域滞留率(20分钟时纹状体最大值:小脑:皮质约为1.1:1:0.8)与这些区域中已知的A2A受体相对密度有很大不同。皮质中的放射性比纹状体和小脑中下降得更快(5至50分钟之间分别下降20%和3 - 7%)。向[N-11C-甲基]KF 17837中添加载体仅对脑放射性示踪剂摄取产生轻微影响。相比之下,在心脏中,初始示踪剂摄取量很高,并且添加未标记的载体可增强消除动力学。因此我们表明KF 17837能够通过血脑屏障,尽管程度非常低。这一事实以及[N-11C-甲基]KF 17837在受体密度低的区域体内明显较高的非特异性结合限制了其作为灵长类动物脑中腺苷A2A受体定量配体的实用性。